Highlights of This Issue  

SPECIAL FEATURES

Location, Location, Location-Makes All the Difference for Hypoxia in Lung Tumors
Amit Maity and Constantinos Koumenis
See article p. 4843

New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers
Augusto Villanueva, Yujin Hoshida, Sara Toffanin, Anja Lachenmayer, Clara Alsinet, Radoslav Savic, Helena Cornella, and Josep M. Llovet

Wnt/\beta-Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy
Luca Gattinoni, Yun Ji, and Nicholas P. Restifo

Poly(ADP-Ribose) Polymerase Inhibition: "Targeted" Therapy for Triple-Negative Breast Cancer
Carey K. Anders, Eric P. Winer, James M. Ford, Rebecca Dent, Daniel P. Silver, George W. Sledge, and Lisa A. Carey

CANCER THERAPY: PRECLINICAL

Comprehensive Analysis of the MYB-NFIB Gene Fusion in Salivary Adenoid Cystic Carcinoma: Incidence, Variability, and Clinicopathologic Significance
Yoshitsugu Mitani, Jie Li, Pulivarthi H. Rao, Yi-jue Zhao, Diana Bell, Scott M. Lippman, Randal S. Weber, Carlos Caulin, and Adel K. El-Naggar

Hypoxia Inducible Factor 1α and Hypoxia Inducible Factor 2α Play Distinct and Functionally Overlapping Roles in Oral Squamous Cell Carcinoma
Gui-quan Zhu, Ya-ling Tang, Ling Li, Min Zheng, Jian Jiang, Xiao-yu Li, Si-xiu Chen, and Xin-hua Liang

Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-Mediated Potentiation of Bortezomib-Induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells
Rekha Rao, Srilatha Nalluri, Warren Fiskus, Andrew Savoie, Kathleen M. Buckley, Kyungsoo Ha, Ramesh Balusu, Atul Joshi, Veena Coothankandaswamy, Jianguo Tao, Eduardo Sotomayor, Peter Atadja, and Kapil N. Bhalla

Mitochondrial-Mediated Apoptosis in Lymphoma Cells by the Diterpenoid Lactone Andrographolide, the Active Component of Andrographis paniculata
Shuo Yang, Andrew M. Evens, Sheila Prachand, Amareshwar T.K. Singh, Savita Bhalla, Kevin David, and Leo I. Gordon

Involvement of Human Herpesvirus-6 Variant B in Classic Hodgkin’s Lymphoma via DR7 Oncoprotein
Aurélie Lacroix, Sophie Collot-Teixeira, Laurent Mardivirin, Arnaud Jaccard, Barbara Petit, Christophe Piquet, Franck Sturz, Pierre-Marie Peux, Dominique Bordessoule, and Sylvie Ranger-Rogete

Molecular Pathways

HUMAN CANCER BIOLOGY

Research...
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4779</td>
<td>Preclinical Characterization of Mitochondria-Targeted Small Molecule Hsp90 Inhibitors, Gambitirinibs, in Advanced Prostate Cancer</td>
<td>Byoung Heon Kang, Markus D. Siegelin, Janet Plescia, Christopher M. Rasket, David S. Garlick, Takehiko Dohi, Jane B. Lian, Gary S. Stein, Lucia R. Languino, and Dario C. Altieri</td>
</tr>
<tr>
<td>4789</td>
<td>Cisplatin-Induced Downregulation of OCTN2 Affects Carnitine Wasting</td>
<td>Cynthia S. Lancaster, Chaoxin Hu, Ryan M. Franke, Kelly K. Filipski, Shelley J. Orwick, Zhaoyuan Chen, Zhili Zuo, Walter J. Loos, and Alex Sparreboom</td>
</tr>
<tr>
<td>4809</td>
<td>Tumor Regression and Curability of Preclinical Neuroblastoma Models by PEGylated SN38 (EZN-2208), a Novel Topoisomerase I Inhibitor</td>
<td>Fabio Pastorino, Monica Loi, Puja Sapra, Pamela Becherini, Michele Cilli, Laura Emionite, Domenico Ribatti, Lee M. Greenberger, Ivan D. Horak, and Mirco Ponzoni</td>
</tr>
<tr>
<td>4822</td>
<td>Detailed Distribution of NK012, an SN-38–Incorporating Micelle, in the Liver and Its Potent Antitumor Effects in Mice Bearing Liver Metastases</td>
<td>Amane Takahashi, Nobuhiro Ohkohchi, Masahiro Yasunaga, Jun-ichiro Kuroda, Yoshikatsu Koga, Hirotsugu Kenmotsu, Taira Kinoshita, and Yasuhiro Matsumura</td>
</tr>
<tr>
<td>4843</td>
<td>Hypoxia in Models of Lung Cancer: Implications for Targeted Therapeutics</td>
<td>Edward E. Graves, Marta Vilalta, Ivana K. Cecic, Janine T. Erler, Phuoc T. Tran, Dean Felsher, Leanne Sayles, Alejandro Sweet-Cordero, Quynh-Thu Le, and Amato J. Giaccia</td>
</tr>
<tr>
<td>4853</td>
<td>Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial</td>
<td>Carol Peña, Chetan Lathia, Minghua Shan, Bernard Escudier, and Ronald M. Bukowski</td>
</tr>
<tr>
<td>4876</td>
<td>Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors</td>
<td>José Baselga, Andres Cervantes, Erika Martinelli, Isabel Chirivella, Klaas Hoekman, Herbert I. Hurwit, Duncan I. Jodrell, Paul Hamberg, Esther Casado, Paul Elvin, Alan Swaisland, Renee Iacona, and Josep Tabernero</td>
</tr>
</tbody>
</table>
Preclinical toxicology analysis of Gamitrinibs. Animals carrying prostate cancer xenografts and treated systemically with vehicle or Gamitrinib-TPP (G-TPP) were sacrificed at the end of treatment and organs were collected and analyzed histologically. A representative image of spleen from the vehicle group is shown. For further details, please see the article by Kang and colleagues on page 4779 of this issue.
Clinical Cancer Research

16 (19)


Updated version  Access the most recent version of this article at:  
http://clincancerres.aacrjournals.org/content/16/19

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.